Why this seasoned money manager sees real upside for this innovative B2B tech startup. on 10/26/2021. Learn More
Change: Change(%):
Volume: Open:
High: Low:
52Wk High: 52Wk Low:

Deciphera’s proprietary switch control platform has generated a diverse clinical pipeline of kinase inhibitor drug candidates including tumor-targeted therapies and immuno-targeted therapies.